main results and the role of chance: Survivors had a lower OS than controls: 3.5 versus 4.4 cm 2 per ovary (P ¼ 0.0004), and lower AMH levels: 10.7 versus 22 pmol/l (P ¼ 0.003). Ovarian markers (OS, AMH, AFC) were worse in patients who received high-dose compared with conventional-dose alkylating agents (P ¼ 0.01 for OS, P ¼ 0.002 for AMH, P , 0.0001 for AFC). Hodgkin lymphoma survivors seemed to have a greater reduction in ovarian reserve than survivors of leukaemia (P ¼ 0.04 for AMH, P ¼ 0.01 for AFC), sarcoma (P ¼ 0.04 for AMH, P ¼ 0.04 for AFC) and other lymphomas (P ¼ 0.04 for AFC). A multiple linear regression analysis showed that procarbazine but not cyclophosphamide nor ifosfamide dose was associated with reduced OS (P ¼ 0.0003), AFC (P ¼ 0.0007), AMH (P , 0.0001) and higher FSH levels (P , 0.0001).
Introduction
The overall increase in cancer prevalence and the significant increase in long-term survival rates have generated worldwide interest in procedures that may preserve fertility in adolescents and young women exposed to gonadotoxic chemotherapy (Gatta et al., 2014) . Gonadotoxicity is a well-known side effect of alkylating agents such as cyclophosphamide, procarbazine, melphalan, busulfan and thiotepa (Whitehead et al., 1983; Teinturier et al., 1998; Couto-Silva et al., 2001) . Acute ovarian failure is rare in survivors of childhood cancer. It was estimated as 6% in the Childhood Cancer Survivor Study (Chemaitilly et al., 2006) and is even lower in the absence of pelvic radiation therapy and high-dose chemotherapy regimens given before haematopoietic stem cell transplantation. Nevertheless, it has been shown that ovarian reserve is lower and that the risk of premature menopause is higher in women who were treated with alkylating agents than in the age-matched general population (Bath et al., 2003; Larsen, Müller, Rechnitzer et al., 2003; Larsen, Muller, Schmiegelow et al., 2003; van Beek et al., 2007; Lie Fong et al., 2009) . The reported incidence of premature menopause, i.e. before 40 years of age, in this population varies from 2% in our study to 8% in the Childhood Cancer Survivor Study (Byrne et al., 1992; Chiarelli et al., 1999; Sklar et al., 2006; Thomas-Teinturier et al., 2013) . However, it will probably increase in future years given the use of intensive chemotherapy over the past 15 years. In addition to infertility, which requires assisted reproductive techniques (in vitro fertilization with a woman's own oocytes or with oocyte donation), premature menopause is associated with an increased incidence of osteoporosis, and higher morbidity and mortality relating to cardiovascular disease (Shuster et al., 2010) . In survivors, it is difficult to predict the extent of reproductive impairment and the window of fertility for family planning. Although assessment of ovarian reserve can predict response and pregnancy in infertile women undergoing assisted reproductive technology, there are few data on its usefulness for counselling young cancer survivors (Larsen, Müller, Rechnitzer et al., 2003; Van Beek et al., 2007; Lie Fong et al., 2009) .
Our aim was to assess the ovarian reserve of follicles in a large homogeneous cohort of childhood cancer survivors treated with alkylating agents without pelvic or total body irradiation or busulfan/thiotepa, to determine the degree of ovarian damage and risk factors associated with such damage.
Materials and Methods

Subjects
Approval for the study was obtained from the local medical research committee, and written informed consent was obtained from all participants. Sample size calculation was performed for ovarian volume based on a mean (+SD) ovarian volume of 6.55 + 1.39 ml in normal women aged 18 -39 years (Kelsey et al., 2013) and anti-Müllerian hormone (AMH) levels based on our normal values, median 20.6 pmol/l (5th-95th percentile 8.5 and 59.8) (Dewailly et al., 2010) . A total of 72 patients should allow us to identify with a power of 80%, a reduction of 1.3 ml in ovarian volume corresponding to the observed reduction between 18 and 40 years of age in the normal population. A total of 48 patients should allow us to identify with a power of 80%, a difference of 10 pmol/l in AMH levels when accepting a risk alpha of 0.05. So, the power of this study with the actual numbers recruited (n ¼ 105) was 93.3% to identify a reduction of 1.3 ml in ovarian volume and 99.2% to identify a difference of 10 pmol/l in AMH levels with the population averages when accepting a risk alpha of 0.05.
The files from five centres computer databases (Institut Gustave Roussy, Institut Curie, Hô pital Trousseau, Hô pital Saint-Louis, Paris and Centre Oscar Lambret, Lille) were screened to identify all patients who met all of the following criteria: aged 17 -40 years, living in or near Paris or Lille, without known ovarian failure, having received alkylating agents during childhood for a sarcoma, neuroblastoma, lymphoma, acute leukaemia or other tumours with .3 years follow-up after the end of treatment, and none of the following exclusion criteria: ovarian tumours, brain or pelvic radiotherapy, or treatment with busulfan or thiotepa. A letter was sent to the 408 identified survivors fulfilling the above criteria. One hundred and forty-five women agreed to participate but only 108 performed the assessment. Of these, three were excluded from the analysis, because their evaluation either diagnosed a polycystic syndrome or was done during the second week of the contraceptive pill (Fig. 1) .
Controls
Twenty healthy controls without any known ovarian problem, aged 15 -34 years, with regular menstrual cycle length before oral contraceptive pills use were recruited by means of advertisement in Saint Vincent de Paul hospital. They had a median age of 21.5 years and thus were slightly younger than patients, the median age of whom was 25 years (17-40) (P ¼ 0.009), and had a lower body mass index (BMI) (20.5 versus 21.4 kg/m 2 , P ¼ 0.02). Seven controls were using oral contraceptive pills. Because our control group is small and younger than the patient group, we also compared patients median ovarian volume to an age-matched validated normative model of ovarian volume (median ¼ 6.3 ml) published by Kelsey and patients median AMH levels to normal values (median ¼ 20.6 pmol/l) published by Dewailly (Dewailly et al., 2010; Kelsey et al., 2013) .
Experimental design
Patients and controls not using an oral contraceptive pill were evaluated during the early follicular phase of the menstrual cycle (cycle Day 2 -5).
The oral contraceptive pill users were asked to stop their pill for at least 1 month before ovarian assessment. Those who did not want to stop their pill were asked to take a 30 mg Ethinyl-Estradiol monophasic pill for at least 1 month and were evaluated on Day 7 of the pill-free interval where gonadotrophin levels have been reported to be not different from their early follicular phase levels (Cohen and Katz, 1981) . Transvaginal or transabdominal (if necessary) ultrasound was performed to measure the volume of both ovaries, and the size and number of antral follicles (AFC). Any finding of pelvic abnormality (uterus, Fallopian tubes) was also recorded. On the same morning, blood samples were collected for hormonal evaluation: follicle-stimulating hormone (FSH), luteinizing hormone (LH) and estradiol serum levels were analysed in the endocrine laboratory of Hô pital Cochin, except in the case of 11 women whose samples were analysed in the endocrine laboratory of Lille Hospital using similar methods. All blood samples were then centrifuged at 1300 g for 10 min at 48C and frozen (2208C) for storage and then analysed in the same run for AMH.
Hormonal assays
FSH and LH were measured as previously described using a time-resolved fluorometric assay with Delfia reagents (PerkinElmer Life Sciences, Courtaboeuf, France). In the FSH assay, intra-and inter-series coefficients of variation were at the level 3.1 IU/l 1.2 and 3.9%, respectively, and at the level Figure 1 Flow chart of survivors.
Ovarian reserve in childhood cancer survivors 16.6 IU/l 1.5 and 2.8%, respectively. In the LH assay, the intra-and interseries coefficients of variation were at the level 0.3 IU/l 1.4 and 2.6%, respectively, and at the level 6.9 IU/l 1.7 and 2.0%, respectively. The sensitivity for both assays was 0.01 IU/l. The estradiol level was measured as previously described in a direct radioimmunoassay using Clinical Assays reagents (Diasorin, Antony, France). Intra-and inter-series coefficients of variation at the level of 96 pmol/l were 5.8 and 2.4%, respectively. The sensitivity was 7 pmol/l. Serum AMH levels were assessed using the second-generation enzyme immunoassay AMH-EIA (Immunotech, Beckman Coulter, Marseille, France). Intra-and inter-assay coefficients of variation were ,12.3 and 14.2%, respectively and sensitivity was 2.5 pmol/l.
Ultrasound
All transvaginal ultrasound measurements were performed by one of three trained investigators (A.E.M., S.E., C.D.) using a 5 -9 MHz transvaginal probe on a Voluson E8 expert, GE. Twenty-two survivors and 14 controls who were uncomfortable with transvaginal sonography had a transabdominal sonography. An antral follicular count (AFC) was performed by assessing the number of follicles measuring 2 -5 and 5 -10 mm in both the right and left ovaries. Furthermore, the surface area of each ovary and the ovarian volume were estimated using the formulas 0.8 × length × width and d1 × d2 × d3 × p/6 where d1, d2, d3 are the three maximal longitudinal, anteroposterior and transverse diameters. The ovarian surface (OS) area and volume were recorded as the mean value of the right and left ovary.
Ovarian volume was available only in 79 patients and not in controls for technical reasons.
Treatments
The medical records of all survivors were examined, and the cumulative dose of each chemotherapeutic agent was calculated in milligrams per square metre. Radiotherapy was recorded and the irradiation field separated into subdiaphragmatic, susdiaphragmatic, limb or cervical. None of the patients underwent oophorectomy.
Statistical analysis
The results are presented as the median plus range. Correlations between variables were tested using Spearman's correlation analysis (r ¼ correlation coefficient). Comparisons between two independent groups were performed using the Wilcoxon rank test for patients and control groups and with the sign test for the median value observed in patients versus published normal values. The Kruskal -Wallis rank test was performed to analyse the variance of three or more groups, and multiple comparison tests with the Bonferroni correction were performed for the figures. Stepwise, multiple, linear regression analysis was performed to evaluate the most important factors influencing the variations in AFC, OS area, AMH and FSH serum levels. To make the variables better fit the assumptions underlying regression, the distributions of AFC, OS area, AMH and FSH serum levels were normalized by log transformation. The independent variables studied were age at diagnosis, pubertal status at diagnosis, each drug (yes or no) and its cumulative dose, subdiaphragmatic irradiation (yes or no), high-dose chemotherapy with stem cell transplant (yes or no), age at evaluation, oral contraceptive pill use and modality of ultrasound (transvaginal versus transabdominal). P-values of ,0.05 were considered significant. All analyses were performed using SAS software for Windows version 9.3.
Results
One hundred and five female survivors of childhood cancer, aged 17-40 years (median: 25 years) were assessed. The main characteristics of the patients and cancer therapies received are shown in Thirty-five out of 105 survivors and 7 out of 20 controls were taking an estrogen-containing oral contraceptive. Analysis of the main characteristics and results in survivors and controls taking or not taking an estrogencontaining oral contraceptive revealed no statistical difference between the two groups. We analysed ovarian markers stratified by oral contraceptive use or not, and then without this stratification, and the results remained unchanged, so the figures show the results in the whole population.
Comparison of ovarian markers between survivors and controls showed a lower OS area: 3.5 versus 4.4 cm 2 per ovary (P ¼ 0.0004) and lower AMH levels: 10.7 versus 22 pmol/l (P ¼ 0.003) in survivors (Table II) . In addition, median ovarian volume in survivors (3.76 ml) was statistically significantly different from the median ovarian volume of 6.3 ml reported in age-matched normal population (P , 0.0001), and median AMH in survivors was also significantly different from the normal median AMH value of 20.6 pmol/l (P , 0.0001). Only eight patients had evidence of altered ovarian function at the time of evaluation, as diagnosed by FSH . 15 UI/l at least twice and AMH , 3.6 pmol/l and amenorrhoea after stopping their pill. In survivors, AFC was correlated with AMH (r ¼ 0.69, P , 0.0001), the number of small follicles ,5 mm (r ¼ 0.66, P , 0.0001) and to a lesser extent OS area (r ¼ 0.42, P , 0.0001). AMH was also correlated with OS area (r ¼ 0.45, P , 0.0001) and negatively with FSH (r ¼ 20.57, P , 0.0001) (Supplementary data, Table SI) .
Survivors were divided into three groups based on the treatment they received-alkylating agents alone, alkylating agents and subdiaphragmatic radiotherapy or high-dose alkylating agents. In all therapeutic groups, survivors had a lower OS area and AMH levels compared with the controls (Fig. 2) . This was confirmed by comparative analysis with published normal values. Ovarian markers (OS, AMH, AFC) were worse in patients given high-dose alkylating agents compared with those treated with a conventional dose of alkylating agents (P ¼ 0.01 for OS area, P ¼ 0.002 for AMH and P , 0.0001 for AFC). The total number of antral follicles was significantly reduced only in these survivors Ovarian reserve in childhood cancer survivors (P ¼ 0.0004). An increase in FSH levels over controls was observed only in patients who had received alkylating agents and subdiaphragmatic radiotherapy (12/19 have been treated for HL) (P ¼ 0.0009).
We then studied ovarian markers according to the five types of cancer-ALL, HL, NHL, sarcoma and neuroblastoma with miscellaneous tumours (Fig. 3) . Although AMH levels were significantly lower in Ovarian volume was compared with median ovarian volume reported by Kelsey et al. (2013) for women aged 18-39 years and AMH levels with normal values reported by Dewailly et al. (2010) .
survivors of all types of cancer other than ALL and sarcoma compared with the controls, OS area was significantly reduced only in HL, neuroblastoma and sarcoma survivors. This was confirmed by comparative analysis with published normal values. The somewhat reduced AFC in HL survivors did not reach significance compared with the controls (P ¼ 0.07). HL survivors had a significantly lower ovarian reserve than other survivors as demonstrated by the lower AMH levels as well as AFC and OS area, and higher FSH levels, compared with survivors of ALL (P ¼ 0.04 for AMH, P ¼ 0.02 for FSH, P ¼ 0.01 for AFC), sarcoma (P ¼ 0.04 for AMH, P ¼ 0.001 for FSH, P ¼ 0.04 for AFC, P ¼ 0.02 for OS area), NHL (P ¼ 0.004 for FSH, P ¼ 0.04 for AFC, P ¼ 0.04 for OS area). Neuroblastoma survivors had a reduced OS area and antral follicular count compared with ALL (P ¼ 0.05 and 0.009) and sarcoma survivors (P ¼ 0.006 and 0.04).
To identify factors influencing the variations in AFC, OS area, AMH and FSH serum levels, a linear regression analysis was performed (Supplementary data, Table SII) . A stepwise, multiple, linear regression analysis was performed controlling for the use of oral contraceptive pill and modalities of ovarian sonography for OS area and AFC. In the final model explaining 24-42% of the variance depending on the tested variable, predictors were age at evaluation, procarbazine dose and a history of high-dose alkylating agents (Table III) . The use of an oral contraceptive pill as a factor of low AMH serum levels was on the borderline of statistical significance (P ¼ 0.05). Age or pubertal status at treatment, subdiaphragmatic irradiation and the total cumulative dose of cyclophosphamide or ifofasmide were not predictive factors for markers of ovarian reserve. As procarbazine therapy was strongly associated with HL (20/23 patients who received procarbazine were treated for HL and 20/21 patients with HL received procarbazine (Table I) ), it seems impossible to separate the effects of this drug and the type of cancer.
Discussion
This is the largest study with a detailed analysis of markers of ovarian reserve in a population of survivors of childhood cancer who all received alkylating agents without direct pelvic radiotherapy and with no known ovarian failure. Only 8/105 (8%) patients were diagnosed with unknown altered ovarian function at the time of evaluation (FSH . 15 UI/l at least twice, AMH , 3.6 pmol/l and amenorrhoea after stopping oral contraceptive use). However, only 16 women aged .30 years agreed to participate, 2 of which had premature ovarian failure (13%). Their limited number is not sufficient to draw conclusions regarding the incidence of premature ovarian failure in this population. Reasons for non-participation in this study in the case of women aged . 30 may bias the results, for example, they may already have children or conversely may have known ovarian failure.
Comparison of markers of ovarian reserve between controls and survivors showed significant impairment in the size of the ovaries and AMH indicates the median of the data, the circle the mean, the bottom and top of the box the 25th and 75th percentiles. The whiskers represent the outliers. ALL, acute lymphoblastic leukaemia; HL, Hodgkin lymphoma; NHL, non-Hodgkin lymphoma; NRB, neuroblastoma. levels. No significant difference was detected in AFC between survivors and controls, although there was a significant difference between survivors of ALL and HL. This could be due to the high percentage of transabdominal ultrasound in our controls (70%), which is associated with a lower AFC compared with transvaginal ultrasound, because of its lower resolution. We were able to compare the effect of specific chemotherapeutic regimens on ovarian reserve in this study. This revealed that only procarbazine treatment (and not cyclophosphamide or ifofasmide treatment) was associated with a diminished ovarian reserve. But it is worth noting that most patients received ,10 g/m 2 cyclophosphamide. In the absence of high-dose alkylating agents therapy, HL survivors seemed to have a greater reduction in ovarian reserve than other survivors connected to procarbazine dose. Nowadays most HL patients receive protocols without procarbazine with less ovarian damage (Van Beek et al., 2007) . Age and pubertal status at the time of treatment were not associated with diminished ovarian reserve. These findings are consistent with those of Lie Fong et al. (2009) but not with those of Charpentier et al. (2014) and Larsen, Muller, Schmiegelow et al. (2003) . However, procarbazine dose has not been tested as a covariate in the multivariate model in these last two studies, and procarbazine is used in the treatment of HL arising mostly in adolescents. This could be potential confounder in these studies, because an older age at diagnosis of cancer may be linked with procarbazine treatment.
Diminished ovarian reserve in survivors of childhood cancer has already been described in smaller series (Bath et al., 2003; Larsen, Müller, Rechnitzer et al., 2003; Larsen, Muller, Schmiegelow et al., 2003; Van Beek et al., 2007; Gracia et al., 2012; El-Shalakany et al., 2013; Krawczuk-Rybak et al., 2013; Lunsford et al., 2014) . These series have several limitations: small sample size in some cases, inclusion of subjects with various diagnoses and heterogeneous therapies making it impossible to assess the effect of each chemotherapeutic agent and dosage, and inclusion of subjects with known ovarian failure or nonextensive analysis of ovarian markers. Larsen reported that survivors had a smaller ovarian volume (4.8 versus 6.8 ml) and a lower number of antral follicles per ovary (7.5 versus 11) than controls. Ovarian irradiation, alkylating agents, older age at diagnosis and longer time off treatment were associated with a reduced AFC (Larsen, Muller, Schmiegelow et al., 2003) . Gracia reported an impaired ovarian reserve in a heterogeneous prospective cohort of survivors (n ¼ 71), with AMH levels and AFC seeming to be the most sensitive measures for quantifying damage to the ovaries (Gracia et al., 2012) . Lie Fong et al. (2009) reported only AMH serum levels in 185 female survivors of childhood cancer, but the serum samples were taken randomly during the menstrual cycle, and data were studied without taking into account the use of oral contraceptive pills and were compared with controls not taking contraceptive pills. However, there is controversy surrounding the possible reduction in AMH levels due to oral contraceptive pill use in healthy volunteers and the same trend was on the borderline of statistical significance in our patients (P ¼ 0.05) (Van den Berg et al., 2010; Bentzen et al., 2012; Kristensen et al., 2012) . Furthermore, in cancer survivors, Charpentier et al. (2014) found that use of oral contraceptive pills remained significantly associated with lower AMH in their multivariate model. Therefore, this factor could have increased the difference in AMH levels between survivors and controls in this study. Moreover, AMH levels were not measured using the same assay in survivors and controls and even if results were adjusted for comparison this could have biased the global results.
Early detection and follow-up of compromised ovarian function after cancer therapy should help physicians to counsel young survivors about their fertility window and guide fertility preservation strategies when necessary. Nevertheless, the question that remains unanswered is whether a reduction in ovarian reserve truly reflects future fertility impairment and predicts earlier age at menopause in this population. Some findings and our own experience suggest that predictions about future fertility in survivors of childhood cancer based only on one measurement of ovarian reserve are not adequate. Indeed, Dillon et al. (2013) reported that despite diminished ovarian reserve markers, pregnancies were achieved in some survivors with a mean time to conception that seemed longer than in controls, although significance was not reached because of the small numbers involved: 8.6 months (range 0-28) compared with 3.1 months (0-7) (P ¼ 0.3). It is likely that measures of ovarian reserve provide more information about the quantity of ovarian follicles available rather than their quality in young women. Additional studies are needed to better understand the predictive value of these measures for pregnancy rate and time to menopause in this population of young survivors (Ledger, 2010; Loh and Maheshwari, 2011; Nelson et al., 2012) . Longitudinal measurement of ovarian reserve in these patients will be required to study the rate of ovarian reserve decline, pregnancy rate, time taken to achieve pregnancy and age at menopause to answer this question. The results of this study bear out that the patients most at risk of premature ovarian failure are those who are going to receive high-dose alkylating agents therapy and the majority of the others will probably have an opportunity for natural fertility in the absence of direct pelvic radiation. This could help oncologists to offer fertility preservation, in particular the experimental option of ovarian tissue cryopreservation in young girls.
This study has some limitations. First, our control group had a younger median age than the survivors (21.5 versus 25 years), and this could have increased the difference in ovarian markers between the two groups. Nevertheless, when adjusting for age at evaluation, the results remained unchanged. In addition, the number of controls is small, so to strengthen the analysis ovarian volume and AMH levels in survivors were compared with published normal values, and results were absolutely the same. The small percentage of participating survivors (28%) from the total cohort does not allow conclusion on fertility issues, because this cohort may not be representative of the population of survivors, as participating women could be more concerned about their fertility than nonparticipants. The strong association between procarbazine and HL (20/23 patients who received procarbazine were treated for HL) makes it impossible to dissociate their individual impacts on ovarian reserve. Oral contraceptive use may modify hormonal results but as the same percentage of survivors and controls were taking an oral contraceptive, this factor could not have modified the global results. Moreover, multivariate analysis was adjusted according to the use of an oral contraceptive.
This study has several strengths. An extensive evaluation of ovarian reserve was performed and hormone variability was minimized by obtaining early follicular phase measures and by centralizing dosages in only two laboratories. The studied population was selected according to the use of alkylating agents without pelvic or brain radiotherapy to minimize the heterogeneity of treatments received on the basis of known ovarian toxicity.
In conclusion, this study shows that ovarian reserve seems to be reduced particularly in survivors who received procarbazine (most of them for HL) or high-dose alkylating agents before stem cell transplantation. Procarbazine but not cyclophosphamide or ifosfamide dose is associated with diminished ovarian reserve. Currently, counselling young patients with a diminished ovarian reserve after cancer cure is like looking into the crystal ball. Longitudinal follow-up is required to determine the rate of progression from low ovarian reserve to premature ovarian failure.
